Scholarlink

Background <p>Drug resistance, poor treatment response, and low long-term survival rates are major obstacles to the successful long-term treatment of acute myeloid leukemia (AML), a heterogeneous hematologic malignancy. A deeper understanding of the molecular mechanisms underlying AML is therefore essential. Glutamic oxaloacetic transaminase 1 (GOT1), a key metabolic enzyme, has emerged as a potential regulator of AML progression, though its precise role remains unclear. This study aimed to investigate the expression profile, functional significance, and mechanistic involvement of GOT1 in AML.</p> Methods <p>The expression levels of GOT1 in AML patient samples and cell lines were quantified by RT-qPCR and western blotting. Genetic knockdown (shRNA) and pharmacological inhibition (compound 2C) were employed to suppress GOT1 activity. Functional assays, including CCK-8 assay and Annexin V/PI staining, evaluated proliferation and apoptosis of AML cells. Multi-omics analyses (transcriptomics, proteomics, and metabolomics) were performed to delineate the mechanistic landscape of GOT1 inhibition. Reactive oxygen species (ROS) levels, glutathione (GSH) content, malondialdehyde (MDA) levels, and nicotinamide adenine dinucleotide phosphate (NADPH) levels in AML cells treated with compound 2C were measured. The combined effects of compound 2C and ferroptosis inducers (RSL3 or FIN56) were evaluated using the CCK-8 assay and Annexin V/PI staining. Synergy scores were calculated by SynergyFinder analysis based on the HSA reference model.</p> Results <p>The expression of GOT1 was significantly upregulated in AML patients and cell lines compared to controls. Inhibition of GOT1 suppressed AML proliferation and induced cell death via triggering ferroptosis. Multi-omics profiling revealed perturbations in redox homeostasis and iron metabolism pathways upon GOT1 suppression. Notably, GOT1 inhibition (compound 2C) combined with ferroptosis inducers (RSL3 or FIN56) synergistically reduced AML cell viability and induced apoptosis.</p> Conclusion <p>Our findings demonstrate that GOT1 drives AML progression by modulating ferroptosis susceptibility. Targeting GOT1, either alone or in combination with ferroptosis inducers, represents a novel therapeutic strategy to overcome resistance and improve outcomes in AML.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Inhibition of GOT1 potentiates ferroptosis and exacerbates cell death in acute myeloid leukemia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月31日

查看全文
  • Huan Peng,
  • Fangshu Liu,
  • Wenjue Tang,
  • Xin Lin,
  • Qiongyou Liang,
  • Qinle Zhang,
  • Huihong Dou,
  • Sheng He

摘要

Background

Drug resistance, poor treatment response, and low long-term survival rates are major obstacles to the successful long-term treatment of acute myeloid leukemia (AML), a heterogeneous hematologic malignancy. A deeper understanding of the molecular mechanisms underlying AML is therefore essential. Glutamic oxaloacetic transaminase 1 (GOT1), a key metabolic enzyme, has emerged as a potential regulator of AML progression, though its precise role remains unclear. This study aimed to investigate the expression profile, functional significance, and mechanistic involvement of GOT1 in AML.

Methods

The expression levels of GOT1 in AML patient samples and cell lines were quantified by RT-qPCR and western blotting. Genetic knockdown (shRNA) and pharmacological inhibition (compound 2C) were employed to suppress GOT1 activity. Functional assays, including CCK-8 assay and Annexin V/PI staining, evaluated proliferation and apoptosis of AML cells. Multi-omics analyses (transcriptomics, proteomics, and metabolomics) were performed to delineate the mechanistic landscape of GOT1 inhibition. Reactive oxygen species (ROS) levels, glutathione (GSH) content, malondialdehyde (MDA) levels, and nicotinamide adenine dinucleotide phosphate (NADPH) levels in AML cells treated with compound 2C were measured. The combined effects of compound 2C and ferroptosis inducers (RSL3 or FIN56) were evaluated using the CCK-8 assay and Annexin V/PI staining. Synergy scores were calculated by SynergyFinder analysis based on the HSA reference model.

Results

The expression of GOT1 was significantly upregulated in AML patients and cell lines compared to controls. Inhibition of GOT1 suppressed AML proliferation and induced cell death via triggering ferroptosis. Multi-omics profiling revealed perturbations in redox homeostasis and iron metabolism pathways upon GOT1 suppression. Notably, GOT1 inhibition (compound 2C) combined with ferroptosis inducers (RSL3 or FIN56) synergistically reduced AML cell viability and induced apoptosis.

Conclusion

Our findings demonstrate that GOT1 drives AML progression by modulating ferroptosis susceptibility. Targeting GOT1, either alone or in combination with ferroptosis inducers, represents a novel therapeutic strategy to overcome resistance and improve outcomes in AML.